CXCR2 and myasthenia gravis: To investigate the role of neutrophils during the acute exacerbation of MG, we first established an EAMG model and intervened with the CXCR2 inhibitor SB225002 (2 mg kg−1 day−1, intraperitoneal injection) to explore the mechanism of neutrophil release from the bone marrow into the peripheral blood (Figure 6K).